AbbVie: Navigating the Post-Humira Landscape
Cashu Finance·4 min read

TL;DR
- AbbVie adapts post-Humira with innovative therapies.
- Strong sales from Skyrizi and Rinvoq offset Humira losses.
- Promising pipeline with strategic acquisitions boosts outlook.
AbbVie: Navigating the Post-Humira Landscape
AbbVie Inc. (ABBV) is strategically evolving as it transitions away from its once-flagship drug, Humira. With the expiration of Humira's patent, the company faces both challenges and opportunities, re-aligning its business model to bolster growth through innovative therapies and an expanded product portfolio. This article examines AbbVie's current initiatives, competitive standing, and future outlook in light of the changing biopharmaceutical landscape.
The Decline of Humira: An Industry Shift
Historically, Humira has been the cornerstone of AbbVie’s business model, generating substantial revenue through its effectiveness in treating autoimmune diseases such as rheumatoid arthritis and Crohn's disease. However, the entry of biosimilars into the market has created significant challenges for AbbVie. Recent reports reveal a dramatic 30.6% drop in Humira’s revenue, descending to $683 million from nearly $1 billion last year. This startling decline underscores the urgency for AbbVie to pivot its business strategy as it navigates this impending loss.
Despite the concerning trends associated with Humira, AbbVie is not sitting idly by. The company has already demonstrated resilience in its portfolio diversification efforts. Sales from newer drugs, including Skyrizi and Rinvoq, have seen substantial growth, effectively offsetting some of the losses expected from Humira. For instance, Skyrizi has generated an impressive $5.7 billion in a recent quarter alone, affirming its potential to become a key revenue driver. This aligns with earlier discussions about the pressure AbbVie is under and its strategic innovations to weather this transition effectively.This previous article highlights the strong performances from Skyrizi and Rinvoq as vital components of AbbVie’s growth narrative.
Despite the concerning trends associated with Humira, AbbVie is not sitting idly by. The company has already demonstrated resilience in its portfolio diversification efforts. Sales from newer drugs, including Skyrizi and Rinvoq, have seen substantial growth, effectively offsetting some of the losses expected from Humira. For instance, Skyrizi has generated an impressive $5.7 billion in a recent quarter alone, affirming its potential to become a key revenue driver. This aligns with earlier discussions about the pressure AbbVie is under and its strategic innovations to weather this transition effectively.This previous article highlights the strong performances from Skyrizi and Rinvoq as vital components of AbbVie’s growth narrative.

